This study developed and validated a deep learning-based diagnostic model with uncertainty estimation to aid radiologists in the preoperative differentiation of pathological subtypes of renal cell carcinoma (RCC) based on computed tomography (CT) images. Data from 668 consecutive patients with pathologically confirmed RCC were retrospectively collected from Center 1, and the model was trained using fivefold cross-validation to classify RCC subtypes into clear cell RCC (ccRCC), papillary RCC (pRCC), and chromophobe RCC (chRCC). An external validation with 78 patients from Center 2 was conducted to evaluate the performance of the model. In the fivefold cross-validation, the area under the receiver operating characteristic curve (AUC) for the classification of ccRCC, pRCC, and chRCC was 0.868 (95% CI, 0.826-0.923), 0.846 (95% CI, 0.812-0.886), and 0.839 (95% CI, 0.802-0.88), respectively. In the external validation set, the AUCs were 0.856 (95% CI, 0.838-0.882), 0.787 (95% CI, 0.757-0.818), and 0.793 (95% CI, 0.758-0.831) for ccRCC, pRCC, and chRCC, respectively. The model demonstrated robust performance in predicting the pathological subtypes of RCC, while the incorporated uncertainty emphasized the importance of understanding model confidence. The proposed approach, integrated with uncertainty estimation, offers clinicians a dual advantage: accurate RCC subtype predictions complemented by diagnostic confidence metrics, thereby promoting informed decision-making for patients with RCC.

This work aims to perform a cross-site validation of automated segmentation for breast cancers in MRI and to compare the performance to radiologists. A three-dimensional (3D) U-Net was trained to segment cancers in dynamic contrast-enhanced axial MRIs using a large dataset from Site 1 (n = 15,266; 449 malignant and 14,817 benign). Performance was validated on site-specific test data from this and two additional sites, and common publicly available testing data. Four radiologists from each of the three clinical sites provided two-dimensional (2D) segmentations as ground truth. Segmentation performance did not differ between the network and radiologists on the test data from Sites 1 and 2 or the common public data (median Dice score Site 1, network 0.86 vs. radiologist 0.85, n = 114; Site 2, 0.91 vs. 0.91, n = 50; common: 0.93 vs. 0.90). For Site 3, an affine input layer was fine-tuned using segmentation labels, resulting in comparable performance between the network and radiologist (0.88 vs. 0.89, n = 42). Radiologist performance differed on the common test data, and the network numerically outperformed 11 of the 12 radiologists (median Dice: 0.85-0.94, n = 20). In conclusion, a deep network with a novel supervised harmonization technique matches radiologists' performance in MRI tumor segmentation across clinical sites. We make code and weights publicly available to promote reproducible AI in radiology.

Techniques are developed for generating uncertainty estimates for convolutional neural network (CNN)-based methods for registering the locations of lesions between the craniocaudal (CC) and mediolateral oblique (MLO) mammographic X-ray image views. Multi-view lesion correspondence is an important task that clinicians perform for characterizing lesions during routine mammographic exams. Automated registration tools can aid in this task, yet if the tools also provide confidence estimates, they can be of greater value to clinicians, especially in cases involving dense tissue where lesions may be difficult to see. A set of deep ensemble-based techniques, which leverage a negative log-likelihood (NLL)-based cost function, are implemented for estimating uncertainties. The ensemble architectures involve significant modifications to an existing CNN dual-view lesion registration algorithm. Three architectural designs are evaluated, and different ensemble sizes are compared using various performance metrics. The techniques are tested on synthetic X-ray data, real 2D X-ray data, and slices from real 3D X-ray data. The ensembles generate covariance-based uncertainty ellipses that are correlated with registration accuracy, such that the ellipse sizes can give a clinician an indication of confidence in the mapping between the CC and MLO views. The results also show that the ellipse sizes can aid in improving computer-aided detection (CAD) results by matching CC/MLO lesion detects and reducing false alarms from both views, adding to clinical utility. The uncertainty estimation techniques show promise as a means for aiding clinicians in confidently establishing multi-view lesion correspondence, thereby improving diagnostic capability.

To establish a reliable machine learning model to predict malignancy in breast lesions identified by ultrasound (US) and optimize the negative predictive value to minimize unnecessary biopsies. We included clinical and ultrasonographic attributes from 1526 breast lesions classified as BI-RADS 3, 4a, 4b, 4c, 5, and 6 that underwent US-guided breast biopsy in four institutions. We selected the most informative attributes to train nine machine learning models, ensemble models and models with tuned threshold to make inferences about the diagnosis of BI-RADS 4a and 4b lesions (validation dataset). We tested the performance of the final model with 403 new suspicious lesions. The most informative attributes were shape, margin, orientation and size of the lesions, the resistance index of the internal vessel, the age of the patient and the presence of a palpable lump. The highest mean negative predictive value (NPV) was achieved with the K-Nearest Neighbors algorithm (97.9%). Making ensembles did not improve the performance. Tuning the threshold did improve the performance of the models and we chose the algorithm XGBoost with the tuned threshold as the final one. The tested performance of the final model was: NPV 98.1%, false negative 1.9%, positive predictive value 77.1%, false positive 22.9%. Applying this final model, we would have missed 2 of the 231 malignant lesions of the test dataset (0.8%). Machine learning can help physicians predict malignancy in suspicious breast lesions identified by the US. Our final model would be able to avoid 60.4% of the biopsies in benign lesions missing less than 1% of the cancer cases.

The purpose of this study is to assess segmentation reproducibility of artificial intelligence-based algorithm, TotalSegmentator, across 34 anatomical structures using multiphasic abdominal CT scans comparing unenhanced, arterial, and portal venous phases in the same patients. A total of 1252 multiphasic abdominal CT scans acquired at our institution between January 1, 2012, and December 31, 2022, were retrospectively included. TotalSegmentator was used to derive volumetric measurements of 34 abdominal organs and structures from the total of 3756 CT series. Reproducibility was evaluated across three contrast phases per CT and compared to two human readers and an independent nnU-Net trained on the BTCV dataset. Relative deviation in segmented volumes and absolute volume deviations (AVD) were reported. Volume deviation within 5% was considered reproducible. Thus, non-inferiority testing was conducted using a 5% margin. Twenty-nine out of 34 structures had volume deviations within 5% and were considered reproducible. Volume deviations for the adrenal glands, gallbladder, spleen, and duodenum were above 5%. Highest reproducibility was observed for bones (- 0.58% [95% CI: - 0.58, - 0.57]) and muscles (- 0.33% [- 0.35, - 0.32]). Among abdominal organs, volume deviation was 1.67% (1.60, 1.74). TotalSegmentator outperformed the reproducibility of the nnU-Net trained on the BTCV dataset with an AVD of 6.50% (6.41, 6.59) vs. 10.03% (9.86, 10.20; p < 0.0001), most notably in cases with pathologic findings. Similarly, TotalSegmentator's AVD between different contrast phases was superior compared to the interreader AVD for the same contrast phase (p = 0.036). TotalSegmentator demonstrated high intra-individual reproducibility for most abdominal structures in multiphasic abdominal CT scans. Although reproducibility was lower in pathologic cases, it outperforms both human readers and a nnU-Net trained on the BTCV dataset.

Accurately distinguishing histological subtypes and risk categorization of thymomas is difficult. To differentiate the histologic risk categories of thymomas, we developed a combined radiomics model based on non-enhanced and contrast-enhanced computed tomography (CT) radiomics, clinical, and semantic features. In total, 360 patients with pathologically-confirmed thymomas who underwent CT examinations were retrospectively recruited from three centers. Patients were classified using improved pathological classification criteria as low-risk (LRT: types A and AB) or high-risk (HRT: types B1, B2, and B3). The training and external validation sets comprised 274 (from centers 1 and 2) and 86 (center 3) patients, respectively. A clinical-semantic model was built using clinical and semantic variables. Radiomics features were filtered using intraclass correlation coefficients, correlation analysis, and univariate logistic regression. An optimal radiomics model (Rad_score) was constructed using the AutoML algorithm, while a combined model was constructed by integrating Rad_score with clinical and semantic features. The predictive and clinical performances of the models were evaluated using receiver operating characteristic/calibration curve analyses and decision-curve analysis, respectively. Radiomics and combined models (area under curve: training set, 0.867 and 0.884; external validation set, 0.792 and 0.766, respectively) exhibited performance superior to the clinical-semantic model. The combined model had higher accuracy than the radiomics model (0.79 vs. 0.78, p<0.001) in the entire cohort. The original_firstorder_median of venous phase had the highest relative importance among features in the radiomics model. Radiomics and combined radiomics models may serve as noninvasive discrimination tools to differentiate thymoma risk classifications.

Coronary artery disease (CAD) is a major worldwide health concern, contributing significantly to the global burden of cardiovascular diseases (CVDs). According to the 2023 World Health Organization (WHO) report, CVDs account for approximately 17.9 million deaths annually. This emphasizies the need for advanced diagnostic tools such as coronary computed tomography angiography (CCTA). The incorporation of deep learning (DL) technologies could significantly improve CCTA analysis by automating the quantification of plaque and stenosis, thus enhancing the precision of cardiac risk assessments. A recent meta-analysis highlights the evolving role of CCTA in patient management, showing that CCTA-guided diagnosis and management reduced adverse cardiac events and improved event-free survival in patients with stable and acute coronary syndromes. An extensive literature search was carried out across various electronic databases, such as MEDLINE, Embase, and the Cochrane Library. This search utilized a specific strategy that included both Medical Subject Headings (MeSH) terms and pertinent keywords. The review adhered to PRISMA guidelines and focused on studies published between 2019 and 2024 that employed deep learning (DL) for coronary computed tomography angiography (CCTA) in patients aged 18 years or older. After implementing specific inclusion and exclusion criteria, a total of 10 articles were selected for systematic evaluation regarding quality and bias. This systematic review included a total of 10 studies, demonstrating the high diagnostic performance and predictive capabilities of various deep learning models compared to different imaging modalities. This analysis highlights the effectiveness of these models in enhancing diagnostic accuracy in imaging techniques. Notably, strong correlations were observed between DL-derived measurements and intravascular ultrasound findings, enhancing clinical decision-making and risk stratification for CAD. Deep learning-enabled CCTA represents a promising advancement in the quantification of coronary plaques and stenosis, facilitating improved cardiac risk prediction and enhancing clinical workflow efficiency. Despite variability in study designs and potential biases, the findings support the integration of DL technologies into routine clinical practice for better patient outcomes in CAD management.

Brain Tumours are highly complex, particularly when it comes to their initial and accurate diagnosis, as this determines patient prognosis. Conventional methods rely on MRI and CT scans and employ generic machine learning techniques, which are heavily dependent on feature extraction and require human intervention. These methods may fail in complex cases and do not produce human-interpretable results, making it difficult for clinicians to trust the model's predictions. Such limitations prolong the diagnostic process and can negatively impact the quality of treatment. The advent of deep learning has made it a powerful tool for complex image analysis tasks, such as detecting brain Tumours, by learning advanced patterns from images. However, deep learning models are often considered "black box" systems, where the reasoning behind predictions remains unclear. To address this issue, the present study applies Explainable AI (XAI) alongside deep learning for accurate and interpretable brain Tumour prediction. XAI enhances model interpretability by identifying key features such as Tumour size, location, and texture, which are crucial for clinicians. This helps build their confidence in the model and enables them to make better-informed decisions. In this research, a deep learning model integrated with XAI is proposed to develop an interpretable framework for brain Tumour prediction. The model is trained on an extensive dataset comprising imaging and clinical data and demonstrates high AUC while leveraging XAI for model explainability and feature selection. The study findings indicate that this approach improves predictive performance, achieving an accuracy of 92.98% and a miss rate of 7.02%. Additionally, interpretability tools such as LIME and Grad-CAM provide clinicians with a clearer understanding of the decision-making process, supporting diagnosis and treatment. This model represents a significant advancement in brain Tumour prediction, with the potential to enhance patient outcomes and contribute to the field of neuro-oncology.

The goal of this study was to expand our previously created prediction tool (PREDICT-AVF) and web app by estimating long-term primary and secondary patency of radiocephalic AVFs. The data source was 911 patients from PATENCY-1 and PATENCY-2 randomized controlled trials, which enrolled patients undergoing new radiocephalic AVF creation with prospective longitudinal follow up and ultrasound measurements. Models were built using a combination of baseline characteristics and post-operative ultrasound measurements to estimate patency up to 2.5 years. Discrimination performance was assessed, and an interactive web app was created using the most robust model. At 2.5 years, the unadjusted primary and secondary patency (95% CI) was 29% (26-33%) and 68% (65-72%). Models using baseline characteristics generally did not perform as well as those using post-operative ultrasound measurements. Overall, the Cox model (4-6 weeks ultrasound) had the best discrimination performance for primary and secondary patency, with an integrated Brier score of 0.183 (0.167, 0.199) and 0.106 (0.085, 0.126). Expansion of the PREDICT-AVF web app to include prediction of long-term patency can help guide clinicians in developing comprehensive end-stage kidney disease Life-Plans with hemodialysis access patients.

Immunotherapy combined with chemotherapy has improved outcomes for some esophageal squamous cell carcinoma (ESCC) patients, but accurate pre-treatment risk stratification remains a critical gap. This study constructed a deep learning (DL) model to predict survival outcomes in ESCC patients receiving immunotherapy combined with chemotherapy. A DL model was developed to predict survival outcomes in ESCC patients receiving immunotherapy and chemotherapy. Retrospective data from 482 patients across three institutions were split into training (N=322), internal test (N=79), and external test (N=81) sets. Unenhanced computed tomography (CT) scans were processed to analyze tumor and peritumoral regions. The model evaluated multiple input configurations: original tumor regions of interest (ROIs), ROI subregions, and ROIs expanded by 1 and 3 pixels. Performance was assessed using Harrell's C-index and receiver operating characteristic (ROC) curves. A multimodal model combined DL-derived risk scores with five key clinical and laboratory features. The Shapley Additive Explanations (SHAP) method elucidated the contribution of individual features to model predictions. The DL model with 1-pixel peritumoral expansion achieved the best accuracy, yielding a C-index of 0.75 for the internal test set and 0.60 for the external test set. Hazard ratios for high-risk patients were 1.82 (95% CI: 1.19-2.46; P=0.02) in internal test set. The multimodal model achieved C-indices of 0.74 and 0.61 for internal and external test sets, respectively. Kaplan-Meier analysis revealed significant survival differences between high- and low-risk groups (P<0.05). SHAP analysis identified tumor response, risk score, and age as critical contributors to predictions. This DL model demonstrates efficacy in stratifying ESCC patients by survival risk, particularly when integrating peritumoral imaging and clinical features. The model could serve as a valuable pre-treatment tool to facilitate the implementation of personalized treatment strategies for ESCC patients undergoing immunotherapy and chemotherapy.